Biomea Fusion Inc
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
(0.0% 1d) (-24.3% 1m) (-59.2% 1y) (0.0% 2d) (0.0% 3d) (-4.5% 7d) (-13.61% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 390,117,343
https://www.biomeafusion.com
Sec Filling | Patents | 12 employees
Biomea Fusion, Inc. operates as a biopharmaceutical company. The Company focuseS on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion serves customers in the United States.
genetic cancer msa
add to watch list Paper trade email alert is off
Press-releases
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-04-01 (Crawled : 20:00) - globenewswire.com
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: -9.93%
H: 1.6%
C: -7.11%
nasdaq grants
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
Published: 2024-04-01 (Crawled : 13:00) - globenewswire.com
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: 2.68%
H: 5.93%
C: -0.33%
bmf-219 first diabetes
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
Published: 2024-04-01 (Crawled : 13:00) - globenewswire.com
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: 2.68%
H: 5.93%
C: -0.33%
year financial results
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
Published: 2024-03-06 (Crawled : 08:00) - globenewswire.com
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: -16.72%
H: 16.45%
C: 8.29%
alent-111 pancreatic treatment therapy
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-01 (Crawled : 21:00) - globenewswire.com
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
grants
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-09 (Crawled : 16:00) - globenewswire.com
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: -2.07%
H: 5.7%
C: 4.87%
conference
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
Published: 2024-01-08 (Crawled : 14:00) - globenewswire.com
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: 0.61%
H: 7.77%
C: 7.7%
alent-112 first bmf-219 diabetes study
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-02 (Crawled : 21:00) - globenewswire.com
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: 0.89%
H: 1.76%
C: -0.14%
conference
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting
Published: 2023-12-11 (Crawled : 14:30) - globenewswire.com
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: -24.51%
H: 1.49%
C: -7.69%
alent-101 first disease ongoing bmf-219 meeting leukemia study
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219
Published: 2023-12-11 (Crawled : 16:00) - biospace.com/
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: -24.51%
H: 1.49%
C: -7.69%
alent-101 first disease ongoing bmf-219 study
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
| 0000950170-23-067424 | 4 | 2023-12-01 | 2023-11-30 | Buy | A | 1345 | 25543 |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 69% | 31% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
KNW 4 | $0.59 -0.71% 18.64% 27K
|
Manufacturing
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
CLSD | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
14:00
CDZI P 25000 | $2.25 0.0% 260K
|
Utilities
|
14:00
ETST P 39000 | $0.068 -67.14% 43K
|
Manufacturing
|
13:30
FNLC P 1275 | $22.97 3.66% 3.53% 21K
|
Finance
|
12:30
ADMQ | $0.0532 -40.18% 480K
|
|
10:30
AXR P 2400 | $21.0 -5.28% 0.0% 13K
|
Finance
|
21:00
QCRH P 118 | $57.315 3.44% 3.32% 66K
|
Finance
|
18:01
VUZI P 7500 | $1.19 -5.56% -5.88% 550K
|
Electronic Technology
|
18:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10